|
|||||
![]() |
|
Self defense company AXON (NASDAQ:AXON) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 32.8% year on year to $668.5 million. The company’s full-year revenue guidance of $2.69 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $2.12 per share was 45% above analysts’ consensus estimates.
Is now the time to buy AXON? Find out in our full research report (it’s free).
Axon's second quarter drew strong positive market reaction, reflecting the company’s ongoing ability to exceed Wall Street’s expectations. Management credited the company’s robust performance to accelerating adoption of new software solutions, as well as deeper customer relationships across state, local, and international markets. CEO Patrick Smith highlighted rapid uptake of products like Draft One and TASER 10, noting that “demand for new technology from our customers is accelerating, and it’s outpacing even my most optimistic expectations.” The quarter was also characterized by a record-breaking contract in the state and local segment and notable contributions from the corrections and enterprise verticals.
Looking forward, Axon's updated guidance is anchored by continued momentum in its software and AI product portfolio, as well as investments in research and development and new international opportunities. CFO Brittany Bagley emphasized that upcoming tariff-related expenses and increased hiring, especially in R&D, are factored into the company’s outlook. Management believes that sustained growth in annual recurring revenue and ongoing expansion into emerging markets will be key, with Bagley stating, “We continue to expect to increase hiring over the remainder of the year, particularly in R&D, as we prioritize investing behind the incredible product road map.”
Management attributed the quarter’s results to rapid adoption of new software, significant contract wins, and broader product usage across markets.
Axon’s guidance reflects confidence in sustained growth from software and AI adoption, international expansion, and continued product innovation.
Looking ahead, our analysts will focus on (1) the pace of customer upgrades from basic to premium and AI-enabled product bundles, (2) Axon’s ability to manage tariff-driven cost pressures while protecting margins, and (3) execution on large international and enterprise contracts. Progress in R&D hiring and new product launches will also be essential indicators of Axon’s long-term trajectory.
Axon currently trades at $772, up from $742.75 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).
Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.
The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Sep-09 | |
Sep-04 | |
Sep-03 | |
Sep-03 | |
Sep-02 | |
Aug-31 | |
Aug-30 |
These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Amphenol Sets Up
AXON
Investor's Business Daily
|
Aug-29 | |
Aug-28 | |
Aug-28 | |
Aug-27 | |
Aug-27 | |
Aug-26 | |
Aug-25 | |
Aug-20 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite